Vesalio recently announced that it has oversubscribed its Class A financing round. Solas BioVentures led the investment with participation by new and existing investors, including the recent addition of Orlando Health Ventures.
With an expanding customer base established in Europe, Vesalio will use this funding to enter the US market by executing US Food and Drug Administration (FDA) clearances, adding key personnel, developing support infrastructure, expanding its product portfolio, and completing its cardiology clinical study, according to a press release.
“This financing round advances Vesalio’s mission to improve outcomes in patients suffering a stroke and other conditions created by blood clots,” said Mike Kujak, Vesalio board chairman. “As the medical field continues to evolve in treating vascular occlusion, physicians are seeking a device that effectively removes all types of blood clots to improve patient outcomes by reducing the time it takes to restore blood flow. This oversubscribed round of funding allows us to complete the development and introduction of new technology and accelerate the market growth of Vesalio’s proprietary platforms.”
Vesalio also announced a new addition to its board of directors: Bobby Helmedag, the managing director of Orlando Health Ventures. “We are excited to be Vesalio investors,” said Helmedag. “Their NeVa and enVast platforms have shown extremely promising results, and we look forward to supporting them as they scale global markets and enter the US market. And, importantly, CEO Steve Rybka has assembled a top-notch team prepared to drive market penetration through Vesalio’s next wave of growth.”
